Vobarilizumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | IL6R |
| Clinical data | |
| Other names | ALX0061 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1118H1757N315O364S8 |
| Molar mass | 25691.68 g·mol−1 |
Vobarilizumab (INN; development code ALX0061) is a humanized bispecific nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.[1][2][3]
This drug was developed by Ablynx NV to block interleukin-6 receptor. Vobarilizumab has been evaluated in patients with rheumatoid arthritis[4] as well as in lupus.[5]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.
- ^ "A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061". 19 July 2019.
- ^ "A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus". 12 February 2019.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |